SOLICITATION NOTICE
B -- Upper Gastrointestinal (UGI) Cancer Genome-wide Association Study (GWAS)
- Notice Date
- 8/19/2009
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90192-KM
- Archive Date
- 9/18/2009
- Point of Contact
- Karri L. Mares, Phone: 3014357774, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
maresk@mail.nih.gov, cr214i@nih.gov
(maresk@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Genetic Epidemiology Branch (GEB), plans to enter into a sole source procurement for an Upper Gastrointestinal (UGI) Cancer Genome-wide Association Study (GWAS) from Vanderbilt University Medical Center; Sixth Floor, Suite 600; 2525 West End Avenue; Nashville, TN 37203-1738. The services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13. The North American Industry Classification System Code is 621511 and the business size standard $13.5 million. The period of performance shall be for five (5) months from date of award. Esophageal cancer is the fifth leading cause of cancer-related mortality worldwide; whereas gastric cancer is the second leading cause of cancer-related mortality worldwide. Rates are generally higher in developing countries, and lower in North American and Western European countries, with some of the highest rates occurring in China. The goal of this project is to understand the role of germ-line genetic variation, including both single nucleotide polymorphism (SNP) genotype and copy number variation (CNV), in the etiology of upper gastrointestinal (UGI) cancers, defined here as esophageal squamous cell carcinoma (ESCC) and gastric cancer (GC). Though previous studies have investigated the role of individual genetic variation in the etiology of these cancers, little genome wide data is available. There are as yet no published high-density GWAS evaluations in Chinese populations for any conditions, including ESCC or GC. Only recently a GWAS on gastric cancer conducted among Japanese subjects was published. The purpose of the current procurement is to extract DNA from serum from two prospective cohort studies, the Shanghai Men’s Health Study (SMHS) and the Shanghai Women’s Healthy Study (SWHS), for inclusion in the genome-wide association study. Specifically, DNA will be extracted from 32 ESCC cases, 192 GC cases, and 224 controls from the SMHS, along with 27 ESCC cases and 27 controls from the SWHS, standardizing the DNA samples, and shipping them to the NCI. The SMHS and SWHS are unique and carefully conducted prospective cohorts from China, which has the highest or nearly highest rates of UGI cancers of all countries in the world. The above mentioned samples in this study are only available from Vanderbilt University as a result of previous studies conducted by this organization to obtain plasma samples for measuring the major known risk factors for gastric cancer (i.e, Helicobacter pylori, pepsinogen I, and pepsinogen II). The availability of these previously available data are critical and integral to the value and validity of the GWAS being conducted. This is not a solicitation for competitive quotations. However, if any interested party believes it can perform the requirement as detailed they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient details to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the contracting office on or before 11:00 am ET, on September 3, 2009. All questions must be in writing and must be emailed to Karri Mares maresk@mail.nih.gov or faxed to (301) 402-4513. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award from the NCI, contractors must be registered in the Online Representations and Certifications Applications (ORCA). Please refer to http://orca.bpn.gov In addition; contractors must be registered in the Central Contractor Registration (CCR) www.ccr.gov. No collect calls will be accepted. Please reference NCI-90192-KM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90192-KM/listing.html)
- Record
- SN01918265-W 20090821/090820001121-02188a1570cce780887c208a6cf35f46 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |